ntrk1

NTRK1 Gene - Neurotrophic Receptor Tyrosine Kinase 1

Introduction

The NTRK1 gene (Neurotrophic Receptor Tyrosine Kinase 1) encodes the TrkA (Tropomyosin receptor kinase A) receptor, the high-affinity receptor for nerve growth factor (NGF). TrkA is a member of the tropomyosin receptor kinase (Trk) family, which plays critical roles in neuronal survival, differentiation, and function throughout the nervous system. Originally discovered as the receptor for NGF, TrkA has since emerged as a key therapeutic target for multiple neurological disorders, particularly Alzheimer's disease and peripheral neuropathies.

Mutations in NTRK1 cause congenital insensitivity to pain with anhidrosis (CIPA), a rare autosomal recessive disorder characterized by complete loss of pain sensation, anhidrosis (inability to sweat), and often intellectual disability. This demonstrates the essential role of TrkA signaling in pain perception and thermoregulation.

Gene Overview

| Property | Value |
|----------|-------|
| Gene Symbol | NTRK1 |
| Full Name | Neurotrophic Receptor Tyrosine Kinase 1 |
| Alternative Names | TRKA, TrkA |
| Chromosomal Location | 1q21-q22 |
| NCBI Gene ID | 4914 |
| OMIM | 191315 |
| Ensembl ID | ENSG00000164329 |
| UniProt | P35579 |
| Protein Family | Tropomyosin receptor kinase (Trk) family |

NTRK1 Gene - Neurotrophic Receptor Tyrosine Kinase 1

Introduction

The NTRK1 gene (Neurotrophic Receptor Tyrosine Kinase 1) encodes the TrkA (Tropomyosin receptor kinase A) receptor, the high-affinity receptor for nerve growth factor (NGF). TrkA is a member of the tropomyosin receptor kinase (Trk) family, which plays critical roles in neuronal survival, differentiation, and function throughout the nervous system. Originally discovered as the receptor for NGF, TrkA has since emerged as a key therapeutic target for multiple neurological disorders, particularly Alzheimer's disease and peripheral neuropathies.

Mutations in NTRK1 cause congenital insensitivity to pain with anhidrosis (CIPA), a rare autosomal recessive disorder characterized by complete loss of pain sensation, anhidrosis (inability to sweat), and often intellectual disability. This demonstrates the essential role of TrkA signaling in pain perception and thermoregulation.

Gene Overview

| Property | Value |
|----------|-------|
| Gene Symbol | NTRK1 |
| Full Name | Neurotrophic Receptor Tyrosine Kinase 1 |
| Alternative Names | TRKA, TrkA |
| Chromosomal Location | 1q21-q22 |
| NCBI Gene ID | 4914 |
| OMIM | 191315 |
| Ensembl ID | ENSG00000164329 |
| UniProt | P35579 |
| Protein Family | Tropomyosin receptor kinase (Trk) family |

The TrkA receptor is a transmembrane protein composed of an extracellular ligand-binding domain, a transmembrane helix, and an intracellular tyrosine kinase domain. Upon NGF binding, TrkA dimerizes and activates intracellular signaling cascades that promote neuronal survival and function[@barbacid1999].

Protein Structure and Function

Receptor Architecture

The TrkA protein contains several distinct domains:

• Leucine-rich repeat (LRR) motifs for ligand binding
• Cysteine-rich clusters
• Immunoglobulin-like domains
• Responsible for high-affinity NGF binding

• Single alpha-helical segment
• Anchors receptor in the plasma membrane

• Tyrosine kinase catalytic domain
• Multiple tyrosine residues for phosphorylation
• Sites for adaptor protein binding

Signal Transduction Pathways

TrkA activates multiple downstream signaling cascades upon NGF binding[@reichardt2006][@patapoutian2001]:

PI3K/Akt Pathway

The phosphoinositide 3-kinase (PI3K)/Akt pathway is critical for neuronal survival:

• Activation: Autophosphorylation of TrkA creates docking sites for PI3K adaptor proteins (e.g., Shc, IRS-1)
• PI3K activation: Generates phosphatidylinositol (3,4,5)-trisphosphate (PIP3)
• Akt activation: PIP3 recruits Akt to the membrane where it is phosphorylated and activated
• Survival effects: Akt phosphorylates and inhibits pro-apoptotic proteins (Bad, caspase-9)
• Metabolic regulation: Akt promotes glucose metabolism and protein synthesis

MAPK/ERK Pathway

The mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) pathway regulates:

• Neuronal differentiation: Promotes neurite outgrowth and dendritic arborization
• Synaptic plasticity: Modifies synaptic strength and structure
• Gene expression: Activates transcription factors (e.g., CREB) that promote neuronal survival
• Cell cycle: ERK1/2 activation can support neuronal survival under certain conditions

PLC-γ Pathway

Phospholipase C-gamma (PLC-γ) signaling modulates:

• Calcium signaling: PLC-γ hydrolyzes PIP2 to generate inositol trisphosphate (IP3) and diacylglycerol (DAG)
• IP3 receptors: IP3 triggers calcium release from ER stores
• Protein kinase C: DAG activates PKC isoforms
• Synaptic transmission: Calcium dynamics modulate neurotransmitter release

Physiological Roles

TrkA signaling regulates multiple critical functions in the nervous system[@sofroniew2001][@lonze2002]:

Expression Pattern

Tissue Distribution

NTRK1 exhibits selective expression in specific neuronal populations:

| Tissue/Cell Type | Expression | Functional Significance |
|-----------------|------------|------------------------|
| Nociceptive sensory neurons | High | Pain perception |
| Sympathetic neurons | High | Autonomic function |
| Basal forebrain cholinergic neurons | Moderate-High | Memory/learning |
| Melanocytes | High | Pigmentation |
| Mast cells | Moderate | Inflammatory response |

Brain Expression

Within the central nervous system, TrkA is prominently expressed in:

• Basal forebrain cholinergic neurons (BFCNs): The major source of cortical cholinergic innervation
• Hippocampal pyramidal neurons: Critical for memory formation
• Certain cortical interneurons: Modulatory function
• Sensory relay nuclei: Pain and temperature processing

Disease Associations

Congenital Insensitivity to Pain with Anhidrosis (CIPA)

Mutations in NTRK1 cause CIPA (HSAN type IV), characterized by:

• Complete loss of pain sensation: No response to painful stimuli
• Anhidrosis: Inability to sweat, leading to temperature dysregulation
• Intellectual disability: Often present, variable severity
• Self-mutilation: Patients may inadvertently injure themselves

Alzheimer's Disease

The NGF-TrkA pathway is considered a major therapeutic target for Alzheimer's disease for several reasons[@cuello1995][@tuszynski2005]:

Cholinergic Neuron Survival

Basal forebrain cholinergic neurons (BFCNs) are:

• Essential for attention, learning, and memory
• Preferentially lost in AD (early and severe degeneration)
• Dependent on NGF for survival and function

Neuroprotective Effects

NGF-TrkA signaling provides multiple neuroprotective effects in AD models:

Clinical Trials

NGF gene therapy for AD has been explored in clinical trials:

• Phase I trial (Tuszynski et al., 2005): Ex vivo NGF delivery via fibroblasts
• Results: Showed promising evidence of cholinergic neuron preservation
• Challenges: Delivery methods, side effects (weight loss, pain), and dosing
• Current approaches: AAV-mediated gene delivery, small molecule TrkA agonists

Therapeutic Strategies

Several approaches target the NGF-TrkA pathway in AD:

• NGF protein delivery: Direct NGF administration (challenging due to blood-brain barrier)
• Gene therapy: AAV-based NGF or TrkA delivery
• Small molecule agonists: Cell-penetrating NGF mimetics
• TrkB/TrkC cross-activation: Broader neurotrophin receptor activation

Parkinson's Disease

TrkA activation may provide neuroprotective effects in Parkinson's disease:

• Dopaminergic neuron survival: NGF supports dopaminergic neuron viability
• Oxidative stress reduction: TrkA signaling upregulates antioxidant defenses
• Neuroinflammation modulation: Reduces microglial activation
• alpha-synuclein dynamics: May affect protein aggregation pathways

Neuroblastoma

NTRK1 expression in neuroblastoma has complex clinical implications:

• High expression correlates with favorable prognosis
• Reactivation can occur in some tumors
• Chromosomal rearrangements create oncogenic fusion proteins (e.g., TPM3-NTRK1)
• Therapeutic targeting: Larotrectinib and other TRK inhibitors are effective in NTRK fusion-positive tumors[@brodeur2014]

Pathophysiology in Neurodegeneration

Mechanisms of Neuroprotection

The NGF-TrkA pathway protects neurons through multiple interconnected mechanisms:

1. Anti-apoptotic Signaling

The PI3K/Akt pathway:

• Phosphorylates and inhibits Bad (pro-apoptotic BCL-2 family member)
• Inactivates caspase-9
• Promotes survival gene expression via CREB
• Maintains mitochondrial integrity

2. Amyloid-beta Modulation

NGF-TrkA signaling affects amyloid pathology through:

• Reduced amyloid precursor protein (APP) processing
• Enhanced amyloid clearance
• Protection of neurons from amyloid-induced toxicity
• Modulation of amyloid-degrading enzymes

3. Tau Phosphorylation Regulation

TrkA activation influences tau pathology:

• Inhibits GSK-3β (major tau kinase)
• Reduces tau hyperphosphorylation
• Protects against tau-induced neurodegeneration
• Maintains microtubule stability

4. Synaptic Function

TrkA signaling supports synaptic health:

• Preserves cholinergic synapse structure
• Enhances acetylcholine release
• Promotes dendritic spine formation
• Supports activity-dependent plasticity

Why Cholinergic Neurons Are Vulnerable

BFCNs are particularly susceptible in AD for several reasons:

TrkA dysfunction may accelerate cholinergic degeneration, contributing to the characteristic cognitive decline in AD.

Therapeutic Implications

Current Approaches

Several therapeutic strategies target the NGF-TrkA pathway:

Protein and Gene Therapy

• NGF protein delivery: Tested in clinical trials; challenges include delivery and side effects
• AAV-NGF: Viral vector-mediated NGF expression in the brain
• AAV-TrkA: Enhanced TrkA signaling in target neurons
• Cell-based delivery: Ex vivo gene therapy using engineered cells

Small Molecule Agonists

• NGF mimetics: Peptide or small molecule ligands that activate TrkA
• Allosteric activators: Compounds that enhance NGF binding or TrkA activation
• Cell-penetrating variants: Modified NGF that crosses the blood-brain barrier

Advantages of TrkA Agonists

Compared to NGF itself:

• Smaller molecular weight
• Better pharmacokinetic properties
• Reduced off-target effects (e.g., p75NTR)
• More selective TrkA activation

Clinical Development

Challenges and considerations:

Future Directions

Promising research areas include:

• Selective TrkA agonists with improved CNS penetration
• Nanoparticle delivery systems for targeted NGF/agonist delivery
• Gene editing approaches to enhance TrkA signaling
• Biomarker development to select patients and monitor response
• Combination strategies with anti-amyloid or anti-tau therapies

Related Proteins and Pathways

• [NGF (Nerve Growth Factor)](/entities/ngf) — Primary ligand for TrkA
• [BDNF](/entities/bdnf) — Brain-derived neurotrophic factor, TrkB ligand
• [ChAT (Choline Acetyltransferase)](/entities/choline-acetyltransferase) — Acetylcholine synthesis enzyme
• [APP (Amyloid Precursor Protein)](/genes/app) — Amyloid-beta precursor
• [Tau](/proteins/tau) — Microtubule-associated protein

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Nerve Growth Factor Signaling](/mechanisms/nerve-growth-factor-signaling)
• [Neurotrophin Signaling Pathways](/mechanisms/neurotrophin-pathways)
• [Basal Forebrain Cholinergic Neurons](/entities/basal-forebrain-cholinergic-neurons)
• [Allen Human Brain Atlas](https://brain-map.org/)

References

External Links

• [NCBI Gene: NTRK1](https://www.ncbi.nlm.nih.gov/gene/4914)
• [UniProt: P35579](https://www.uniprot.org/uniprot/P35579)
• [OMIM: 191315](https://www.omim.org/entry/191315)
• [HGNC: NTRK1](https://www.genenames.org/data/hgnc_data.php?appid=2&hgnc_id=11918)
• [PharmGKB: NTRK1](https://www.pharmgkb.org/gene/PA162410000)

Pathway Diagram

The following diagram shows the key molecular relationships involving ntrk1 discovered through SciDEX knowledge graph analysis:

Pathway Diagram

The following diagram shows the key molecular relationships involving ntrk1 discovered through SciDEX knowledge graph analysis: